WINNING THE FIGHT AGAINST SUPERBUGS

A global approach

CARB-X accelerates the development of antibiotics, vaccines, diagnostics, and other life-saving products to protect against serious drug-resistant bacterial infections and promote global health security.

GLOBAL REACH

$91M in awards to antibacterial product developers in 7 countries as of July 31, 2018, plus additional funding if R&D project milestones are met.

INNOVATIVE PIPELINE

Growing pipeline of 33 R&D projects including 10 new classes of antibiotics, plus novel targets, non-traditional therapeutics and 5 rapid diagnostics.

ADVANCING PRODUCTS

5 CARB-X projects have achieved Phase 1 or beyond. 6 projects achieved milestone progressions in 2017-2018.

LEVERAGING PRIVATE FUNDS

Companies in CARB-X’s portfolio have raised $9 in private funds for every $1 invested by CARB-X.

2018 FUNDING

Two funding rounds: 1) new classes of direct-acting small and large molecule antibacterials targeting the most challenging Gram-negative bacteria (March), 2) broad call for therapeutics, vaccines, diagnostics and devices (June).

WORLD-RENOVED EXPERTS

CARB-X’s Advisory Board reviews and selects the best science to recommend for funding.

HIGH SCIENTIFIC STANDARDS

CARB-X delivers support and expertise to product developers through its world-class network of accelerators.

STEWARDSHIP & ACCESS

Each CARB-X-funded company is committed to antibiotic stewardship and access.

carb-x.org
Advantages of the CARB-X model:

• The world’s largest early development antibacterial portfolio
• Entrepreneurial dynamic approach to accelerate urgently needed products with funding, business and technical expertise and regulatory assistance
• Focused on the most dangerous drug-resistant bacteria to save lives and improve health security
• Selects and supports the most promising early development research, advancing science and technology with the goal of accelerating the delivery of new products to patients
• Product developers gain access to expertise and global network

Trusted global partnership

• CARB-X is a non-profit public-private partnership dedicated to revitalizing the early development antibacterial pipeline.
• Funded by ASPR/BARDA, Wellcome Trust, the UK Government’s Global Antimicrobial Resistance Innovation Fund (UK GAMRIF) and the Bill & Melinda Gates Foundation, with in-kind support from NIAID, CARB-X is investing more than $500 million in 2016-2021 to accelerate the research and development of new antibiotics, rapid diagnostics, vaccines and other life-saving products.

This fact sheet is supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and awards from Wellcome Trust, the Global AMR Innovation Fund (GAMRIF) funded by the UK Government Department of Health and Social Care (DHSC), and the Bill & Melinda Gates Foundation, as administered by CARB-X. The content is solely the responsibility of the authors and does not necessarily represent the official views of the US Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response or other funders.

FUNDING PARTNERS

ALLIANCE PARTNERS

ACCELERATORS

CARB-X carb-x.org

Published July 31, 2018